Condition: Neuroblastoma · Sponsor: RECORDATI GROUP
This is a non-interventional, multi-national, observational, prospective patient registry to further evaluate the effectiveness and safety of dinutuximab beta - a monoclonal immunoglobulin G 1 (IgG1) antibody, to obtain information on survival, pain severity and incidence of neuro-toxicity, visual impairment, capillary leak syndrome, cardiovascular events, hypersensitivity reactions and long-term safety.
This description comes directly from the study's public registry record.
Jose-Luis Garcia · +34 663 36 34 24 · PASS@eusapharma.com
Always discuss trial participation with your own doctor first.
| St. Anna Kinderkrebsforschung | Vienna, State of Vienna, Austria | Active Not Recruiting |
| Centre Oscar Lambret | Lille, France | Recruiting |
| Hôpital de la Timone, Hôpital des Enfants | Marseille, France | Recruiting |
| Institut Curie | Paris, France | Active Not Recruiting |
| Institut Gustave Roussy | Villejuif, France | Recruiting |
| Charité Berlin | Berlin, Germany | Recruiting |
| Universitätsmedizin Greifswald | Greifswald, Germany | Recruiting |
| IRCCS Istituto Giannina Gaslini | Genova, Italy | Recruiting |
| Uniwersytecki Szpital Dziecięcy | Krakow, Poland | Recruiting |
| Hospital Universitario y Politecnico La Fe Avenida Fernando Abril Martorell | Valencia, Spain | Recruiting |
| The Newcastle upon Tyne Hospitals NHS Foundation Trust | Newcastle upon Tyne, Newcastle, United Kingdom | Recruiting |
| Birmingham Children's Hospital | Birmingham, United Kingdom | Active Not Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04253015